Phase II study with the combination of gemcitabine and DTIC in patients with advanced soft tissue sarcomas

Cancer Chemotherapy and Pharmacology

Volumn 59, Issue 2, 2007, Pages 251-259

  Losa, R ^a   Fra, J ^a   Lopez Pousa A ^b   Sierra, M ^a   Goitia, A ^a   Una E ^a   Nadal, R ^b   Del Muro, J García ^c   Gion M ^a   Maurel, J ^d   Escudero, P ^e   Esteban, E ^a   Buesa, José M ^a  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^c CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^d HOSPITAL CLÍNIC   (Spain)

^e HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

Author keywords

DTIC; Gemcitabine; Pharmacokinetics; Soft tissue sarcomas

Indexed keywords

2',2' DIFLUORODEOXYURIDINE; ANTINEOPLASTIC AGENT; DACARBAZINE; DOXORUBICIN; GEMCITABINE; GEMCITABINE TRIPHOSPHATE; IFOSFAMIDE; TEMOZOLOMIDE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BIOACCUMULATION; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DIARRHEA; DISEASE DURATION; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; DYSPHAGIA; ESOPHAGITIS; FEMALE; FEVER; FLU LIKE SYNDROME; GRANULOCYTE; GRANULOCYTOPENIA; HEMOGLOBIN DETERMINATION; HUMAN; LEIOMYOSARCOMA; LEUKOCYTE COUNT; LIVER TOXICITY; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MALE; MALIGNANT FIBROUS HISTIOCYTOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; REPEATED DRUG DOSE; SIDE EFFECT; SINGLE DRUG DOSE; SOFT TISSUE SARCOMA; STOMATITIS; THROMBOCYTE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ALANINE TRANSAMINASE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; ASPARTATE AMINOTRANSFERASES; DACARBAZINE; DEOXYCYTIDINE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HEMATOLOGIC DISEASES; HUMANS; IFOSFAMIDE; INFUSIONS, INTRAVENOUS; LIVER; LUNG; MALE; MIDDLE AGED; REMISSION INDUCTION; SARCOMA; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 33845366192     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-006-0263-0     Document Type: Article

References (39)

1. Abbruzzese JL, Grunewald R, Weeks EA, Gravel D, Adams T, Nowak B, Mineishi S, Tarassoff P, Satterlee W, Raber MN (1991) Phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 9:491-498
2. Amodio A, Carpano S, Manfredi C, Del Monte G, Di Lauro L, Gionfra T, Conti F, Paoletti G, Lopez M (1999) Gemcitabine in advanced stage soft tissue sarcoma: a phase II study. Clin Ther 150:17-20
3. Beauséjour CM, Gagnon J, Primeau M, Momparler RL (2002) Cytotoxic activity of 2′,2′-difluorodeoxycytidine, 5-aza-2′- deoxycytidine and cytosine arabinoside in cells transduced with deoxycytidine kinase gene. Biochem Biophys Res Commun 293:1478-1484
4. Brennan MF, Singers S, Maki RG, O'Sullivan B (2005) Soft-tissue sarcoma. In: DeVita VT, Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology. Lippincott Williams and Wilkins, Philadelphia, pp 1581-1637
5. Buesa JM, Mouridsen HT, van Oosterom AT, Verweij J, Wagener T, Steward W, Poveda A, Vestlev PM, Thomas D, Sylvester (1991) High-dose DTIC in advanced soft-tissue sarcomas in the adult. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Ann Oncol 2:307-309
6. Buesa JM, Losa R, Fernández A, Sierra M, Esteban E, Díaz A, López-Pousa A, Fra J (2004) Phase I clinical trial of fixed-dose rate infusional gemcitabine and dacarbazine in patients with advanced soft tissue sarcomas with assessment of gemcitabine triphosphate accumulation. Cancer 101:2261-2269
7. Cancer Therapy Evaluation Program (1998) Common toxicity criteria, version 2.0. National Cancer Institute, Bethesda
8. Cattel L, Airoldi M, Passera R, Cagliero F, Stella B, Goffredo F (2004) Gemcitabine plus vinorelbine chemotherapy regimens: a pharmacokinetic study of alternate administration sequences. Pharm World Sci 26:238-241
9. Fossella FV, Lippman SM, Shin DM, Tarassoff P, Calayag-Jung M, Pérez-Soler R, Soo Lee J, Murphy WK, Glisson B, Rivera E, Ki Hong W (1997) Maximum-tolerated dose defined for single-agent gemcitabine: a phase I dose-escalation study in chemotherapy-naïve patients with advanced non-small-cell lung cancer. J Clin Oncol 15:310-316
10. Gautam U, Hurley J, Silva OE, Benedetto PW, Robles C (2002) Gemcitabine: an active chemotherapeutic agent for angiosarcoma (abstract). Proc Annu Meet Am Assoc Clin Oncol 21:278b
11. Gottlieb JA, Benjamin RS, Baker LH, O'Bryan RM, Sinkovics JG, Hoogstraten B, Quagliana JM, Rivkin SE, Bodey GP Sr, Rodriguez V, Blumenschein GR, Saiki JH, Coltman C Jr, Burgess MA, Sullivan P, Thigpen T, Bottomley R, Balcerzak S, Moon TE (1976) Role of DTIC (NSC-45388) in the chemotherapy of sarcomas. Cancer Treat Rep 60:199-203
12. Grunewald R, Abbruzzese JL, Tarasoff P, Plunkett W (1991) Saturation of 2′,2′-difluorodeoxycytidine 5′-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine. Cancer Chemother Pharmacol 27:258-262
13. Hensley ML, Maki R, Venkatraman E, Geller G, Lovegren M, Aghajanian C, Sabbatini P, Tong W, Barakat R, Spriggs DR (2002) Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol 20:2824-2831
14. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481
15. Kroep JR, Giaccone G, Voorn DA, Smit EF, Beijnen JH, Rosing H, Moorsel CJA, van Groeningen CJ, Postmus PE, Pinedo HM, Peters GJ (1999) Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer. J Clin Oncol 17:2190-2197
16. Le Cesne A, Blay JY, van Oosterom A, Verweij J, Radford J, Lorigan P, Rodenhuis S, Ray-Coquard I, Bonvalot S, Collin F, Jimeno J, di Paola E, van Glabbeke M, Nielsen OS (2005) Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organization for the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group trial. J Clin Oncol 23:576-584
17. Leu KM, Ostruszka LJ, Shewach D, Zalupski M, Sondak V, Biermann JS, Lee JS, Couwlier C, Palazzolo K, Baker LH (2004) Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by doxetaxel in the treatment of sarcoma. J Clin Oncol 22:1706-1712
18. Losa R, Siera MI, Blay P, Blanco D, Buesa JM (2004) Determination of gemcitabine triphosphate in peripheral blood mononuclear cells by reverse-phase HPLC. Chromatographia 59:493-496
19. Losa R, Sierra MI, Guardado C, Fernández A, Gión MO, Blanco D, Buesa JM (2005) Development and validation of an ion pair HPLC method for gemcitabine and 2′,2′-difluoro-2′-deoxyuridine determination. Anal Chim Acta 528:255-260
20. Maki RG, Wathen J, Patel SR, Priebat DA, Okuno S, Samuels BL, Harmon DC, Thall PF, Benjamin RS, Baker LH (2005) A sarcoma multicenter phase III study of gemcitabine versus gemcitabine and docetaxel in patients with metastatic soft-tissue sarcomas. In: CTOS 10th annual meeting, Boca Ratón, 19-21 November 2005 (abstract)
21. Merimsky O, Meller I, Flusser G, Kollender Y, Issakov J, Weil-Ben-Arush M, Fenig E, Neuman G, Sapir D, Ariad S, Inbar M (2000) Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: a phase II study. Cancer Chemother Pharmacol 45:177-181
22. Miller AB, Hoogstraten B, Staquet M (1981) Reporting results of cancer treatment. Cancer 47:207-214
23. van Oosterom AT, Mouridsen HT, Nielsen OS, Dombernowsky P, Krzemieniecki K, Judson I, Svancarova L, Spooner D, Hermans C, Van Glabbeke M, Verweij J (2002) Results of randomized studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients. Eur J Cancer 38:2397-2406
24. Patel SR, Gandhi V, Jenkins J, Papadopolous N, Burgess MA, Plager C, Plunkett W, Benjamin RS (2001) Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol 19:3483-3489
25. Pauwels B, Korst AEC, Lambrechts HAJ, Pattyn GGO, de Pooter CMJ, Lardon F, Vermorken JB (2006) The radio-sensitising effect of difluorodeoxyuridine, a metabolite of gemcitabine, in vitro. Cancer Chemother Pharmacol 58:219-228
26. Penz M, Kornek GV, Raderer M, Ulrich-Pur H, Fiebiger W, Lenauer A, Depisch D, Krauss G, Schneeweiss B, Scheithauer W (2001) Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer. Ann Oncol 12:183-186
27. Plunkett W, Huang P, Xu YZ, Heinemann V, Grunewald R, Gandhi V (1995) Gemcitabine metabolism, mechanisms of action and self-potentiation. Semin Oncol 22:3-10
28. Santoro A, Tursz T, Mouridsen H, Verweij J, Steward W, Somers R, Buesa J, Casali P, Spooner D, Rankin E, Kirkpatrick A, van Glabbeke M, van Oosterom A (1995) Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in Wrst-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 13:1537-1545
29. Shepherd FA (1995) Phase II trials of single-agent activity of gemcitabine in patients with advanced non-small cell lung cancer: an overview. Anticancer Drugs 6(Suppl. 6):19-25
30. Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10
31. Späth-Schwalbe E, Genvresse I, Koschuth A, Dietzmann A, Grunewald R, Possinger K (2000) Phase II trial of gemcitabine in patients with pretreated advanced soft tissue sarcomas. Anticancer Drugs 11:325-329
32. Su YB, Sohn S, Krown SE, Livingston PO, Wolchok JD, Quinn C, Williams L, Foster T, Sepkowitz KA, Chapman PB (2004) Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. J Clin Oncol 22:610-616
33. Svancarova L, Blay JY, Judson IR, van Hoesel QG, van Oosterom AT, le Cesne A, Keizer HJ, Hermans C, van Glabbeke M, Verweij J, Hogendoorn PC, Nielsen OS (2002) Gemcitabine in advanced adult soft-tissue sarcomas. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 38:556-559
34. Tempero M, Plunkett W, Ruiz van Haperen V, Hainsworth J, Hochster H, Lenzi R, Abbruzzese J (2003) Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 21:3402-3408
35. Ulrich-Pur H, Kornek GV, Raderer M, Halder K, Kwasny W, Depisch D, Greul R, Scheneeweiss B, Krauss G, Funovics J, Scheithauer W (2000) A phase II trial of biweekly high dose gemcitabine for patients with metastatic pancreatic adenocarcinoma. Cancer 88:2505-2511
36. Van Glabekke M, Verweij J, Judson I, Nielsen OS (2002) Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer 38:543-549
37. Verweij J (2005) Ecteinascidin-743 (ET-743): early test or effective treatment in soft tissue sarcomas? J Clin Oncol 23:5420-5423
38. Wang H, Li M, Rinehart JJ, Zhang R (2004) Dexamethasone as a chemoprotectant in cancer chemotherapy: hematoprotective effects and altered pharmacokinetics and tissue distribution of carboplatin and gemcitabine. Cancer Chemother Pharmacol 53:459-467
39. Zalupski M, Metch B, Balcerzak S, Fletcher WS, Chapman R, Bonnet JD, Weiss GR, Ryan J, Benjamin RS, Baker LH (1991) Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group Study. J Natl Cancer Inst 83:926-932